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AbstrACt
Introduction Staphylococcus aureus bacteremia (SAB) 
is an invasive infection with high mortality and morbidity. 
Rheumatoid arthritis (RA) is associated with increased 
risk of infections due to the disease per se and the use 
of antirheumatic treatments. Few minor studies have 
previously investigated risk of SAB in patients with RA 
and indicated increased risk compared with the general 
population. This nationwide observational study aims to 
investigate incidence of and risk factors for SAB in adult 
patients with RA compared with the general population. 
The effect of disease characteristics (eg, joint erosions, 
disease duration and activity), different antirheumatic 
treatments and smoking on SAB risk will be evaluated.
Methods and analysis All adults (>18 years of age) alive 
and living in Denmark in 1996–2017 will be identified in 
The Danish Civil Registration System. Incident patients 
with RA are identified in the Danish National Patient 
Registry (DNPR) and the nationwide rheumatology 
registry, DANBIO, in which information on, for example, 
antirheumatic treatments, disease characteristics and 
smoking is collected prospectively in routine care. 
Information on comorbidities, invasive procedures and 
prescribed drugs are identified in the DNPR and in The 
Register of Medicinal Product Statistics. Socioeconomic 
status is evaluated in national registers on income and 
education. Incident cases of first-time SAB are identified 
in The Danish National SAB Database. All registers are 
linked on an individual level by unique civil registration 
numbers. Incidence rates and incidence rate ratios will be 
analysed using Poisson regression models and the impact 
of possible risk factors will be evaluated.
Ethics and dissemination All data will be handled in 
accordance with the General Data Protection Regulation 
(EU) 2016/679. No ethical approval is necessary in 
Denmark when handling registry data only. The results 
will be presented in accordance with the Strengthening 
the Reporting of Observational Studies in Epidemiology 
initiative in international peer-reviewed journals and at 
medical conferences.
trial registration number NCT03908086.
IntroduCtIon
Staphylococcus aureus bacteremia (SAB) is an 
invasive infection with an estimated overall 
annual incidence rate (IR) of 36/100 000 
person-years.1 Mortality is high (20%–30%) 
and morbidity significant due to the frequent 
occurrence of secondary infections, for 
example, endocarditis, spondylitis, septic 
arthritis and prosthetic joint infections.1–3 
strengths and limitations of this study
 ► We will identify patients with incident rheuma-
toid arthritis (RA) (the exposure of interest) and 
Staphylococcus aureus bacteremia (SAB) (the out-
come of interest) in a nationwide cohort study in-
cluding all adult Danes (1996–2017) identified by 
national registries.
 ► Nationwide medical databases are used to assess 
SAB incidence rates in the RA cohort and in the 
general population and to evaluate the impact of RA 
disease characteristics and treatments on SAB risk.
 ► We will assess the impact of possible confounding 
factors (eg, comorbidities, surgeries, prescriptions 
and socioeconomic factors) by linkage of national 
registries.
 ► Misclassification of RA and of SAB may occur, re-
sulting in underestimation of the SAB incidence and 
potentially leading the relative estimates towards 
the null.
 ► Data on lifestyle factors (alcohol and smoking) are 
available in the RA cohort but lack in the background 
population. Other factors as illicit drug use, S. aureus 
nasal carriage and presence of central or peripheral 
vascular catheters are generally unavailable.
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SAB among adults is more common in men, in elderly 
individuals and in patients with comorbidities such as 
diabetes mellitus, cancer, hemodialysis, HIV infection, 
heart failure, liver disease, alcohol abuse and intrave-
nous drug abuse.1 4–7 Biofilm of S. aureus can form on 
implanted foreign bodies as prosthetic joints, prosthetic 
heart valves and intravascular devices serving as an infec-
tive focus of SAB.8 Furthermore, S. aureus nasal carriage, 
surgical procedures, treatment with immunosuppressive 
drugs (including glucocorticoids) and low-socioeconomic 
status have been associated with increased risk of SAB4 9–11 
whereas treatment with statins and trimethoprim/sulfa-
methoxazole (TMP/SMX) have been associated with a 
decreased risk.12–14
Rheumatoid arthritis (RA) is a chronic autoimmune 
joint disorder that affects 0.5–1% of the population.15 
Genetic factors, female sex, smoking and low-socioeco-
nomic status increases the risk of RA.15–17 Joint inflam-
mation can lead to joint destruction, and patients with 
RA more often have joint replacements than the general 
population.18 RA is associated with an increased risk 
of other chronic diseases such as diabetes mellitus and 
cardiovascular disease.19 20
Patients with RA are at increased risk of infections 
affecting, for example, lungs, joints and bones.21 22 This 
has been observed even before the era of widespread use 
of the immunosuppressing disease-modifying antirheu-
matic drugs (DMARDs) and glucocorticoids, indicating 
that the immune defense is compromised in patients with 
RA irrespective of treatment.23 24 Furthermore, high RA 
disease activity has been reported to increase the risk of 
infections.25 Antirheumatic treatments such as biologic 
DMARDS (bDMARDs, eg, tumour necrosis factor alpha 
inhibitors (anti-TNFs))26–28 and the newer targeted 
synthetic DMARDs (tsDMARDs, eg, tofacitinib and baric-
itinib)29 30 as well as glucocorticoids22 31–33 have been 
found to be associated with increased risk of infections in 
patients with RA. Recent studies have, however, reported 
that the risk of serious infections using bDMARDs is 
minimal/insignificant suggesting a successful change in 
management of patients through screening for infections 
prior to start of bDMARDs, prophylactic measures as 
vaccines and treating infections early.27 34
Patients with RA are likely at increased risk of SAB due 
to the RA disease per se (altered immunological response 
to infections due to systemic inflammation and local 
inflammation in joints leading to erosions), or due to 
the antirheumatic treatment and the prevalence of joint 
prostheses and comorbidities. Despite the severity of SAB, 
the incidence and risk factors for SAB among patients 
with RA are poorly investigated. Two previous studies of 
SAB incidence in adult patients with RA, both character-
ised by few events of SAB in patients with RA, reported 
incidence rate ratios (IRRs) of 2.6 (95% CI 1.8 to 3.7)4 
and 9.2 (95% CI 1 to 20)7 compared with the back-
ground population. One small nested case–control study 
reported indwelling central venous catheters (OR 15.97, 
95% CI 5.09 to 50.10) and congestive heart failure (OR 
2.89, 95% CI 1.26 to 6.63) as risk factors for RA patients 
being hospitalised with SAB. The study found no associ-
ation between neither conventional synthetic DMARDs 
(csDMARDs), bDMARDs, glucocorticoids nor prosthetic 
joints and SAB.35 However, their comparisons were RA 
patients hospitalised for other reasons than SAB. These 
patients were likely at higher risk of SAB than RA patients 
in general, which may have biassed the relative estimates 
towards no association. Thus, the evidence gap regarding 
SAB in patients with RA is substantial: the incidence of 
SAB in the RA population is unknown and there is insuf-
ficient knowledge on risk factors for SAB.
This protocol presents a nationwide observational 
cohort study of SAB focusing on IRs and risk factors in 
adult patients with RA compared with the adult general 
population. The study is expected to become the largest 
and most detailed of its kind due to the availability of 
unique national registries of microbiologically verified 
cases of SAB and of RA patients’ demographics, anti-
rheumatic treatment, disease characteristics and disease 
activity including patient-reported outcomes, combined 
with the possibility of linking to other national regis-
tries with information on, for example, comorbidities 
(hospital contacts and prescriptions) and socioeconomic 
parameters (education and income). Further, the study 
is expected to conclude whether different antirheumatic 
treatments are associated with different risk of SAB in the 
RA population.
We hypothesise that patients with RA are at increased 
risk of SAB compared with the background population. 
We expect that higher age, male sex, glucocorticoid use 
and joint prostheses increase this risk in both patients 
with RA and the background population, and we hypoth-
esise that additional RA disease-specific factors (eg, high 
disease activity, presence of joint erosions, long disease 
duration, DMARD treatment and smoking) might be 
associated with higher risk in patients with RA. The objec-
tives of the study are to (1) assess the IRs and IRRs of SAB 
in patients with RA compared with the general popula-
tion; (2) explore the significance of age, gender, gluco-
corticoid use and prosthetic joints on SAB risk in patients 
with RA compared with the general population; and (3) 
identify RA disease-specific risk factors for SAB within the 
RA cohort and assess the effect of smoking on SAB risk in 
the RA cohort.
MEthods And AnAlysIs
study design and population
Nationwide observational cohort study of SAB inci-
dence and risk factors in adult patients with RA and in 
the general adult population. The population consists of 
all Danish inhabitants aged 18 years or more, alive and 
living in Denmark in the period from 1996 until 2017 as 
identified by the Danish Civil Registration System (CRS) 
(table 1). Individuals with one of the following prior to 
start of follow-up will be excluded: (1) SAB (the outcome 
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Table 1 Data sources, Danish national registries
The Danish Civil Registration system Established in year 1968. All persons alive and living in Denmark are registered for 
administrative use. Includes complete information on civil registration number, name, 
gender, date of birth and continuously updated information on vital status, marital 
status and place of residence (including immigration and emigration).41
The Danish National Patient Registry Diagnoses listed according to the International Classification of Diseases (ICD) codes 
from all hospital admissions (from 1977) and outpatient activities (from 1995) in the 
form of the 8th revision of the ICD (ICD-8) until 1994 and the 10th revision (ICD-10) 
thereafter. Contains information on surgeries and other procedures performed at 
hospitals. The register is practically complete.42
The Danish Rheumatology Database, 
DANBIO
Initiated in year 2000. Danish national clinical quality registry of rheumatologic patients 
treated with biologics. In 2006, it became mandatory to register all newly diagnosed 
RA patients regardless of treatment. >30 000 patients with RA have been registered 
(unpublished data).
Contains information on for example, ICD-10 diagnosis code of inflammatory 
rheumatic disease, date of diagnosis, symptom duration, auto-antibody status of 
rheumatoid factor (RF) and anticitrullinated peptide antibodies (ACPA), current and 
previous treatment with biologic and synthetic disease-modifying antirheumatic 
drugs (DMARDs), treatment with glucocorticoids (injection, oral), X-ray results (hands 
and feet) and prospectively collected disease activity measures including C reactive 
protein (CRP) and patient-reported outcomes.
Smoking, alcohol consumption and body mass index (BMI) is also registered.43
The Danish National Staphylococcus 
aureus Bacteremia Database
The nationwide registration of S. aureus bacteremias in Denmark since 1957 
carried out by the Staphylococcal Laboratory at the Statens Serum Institut (SSI) for 
surveillance purposes. Linked to civil registration numbers since 1992. The regional 
microbiology departments send isolates on a voluntary basis. Has a high degree of 
completeness and >90% of strains isolated from Danish blood cultures are referred to 
SSI for typing (detection S. aureus protein A (SPA) type) and antibiotic susceptibility 
testing.44
The Register of Medicinal Product 
Statistics
Information on all prescriptions dispensed from pharmacies has been recorded from 
1995 including the anatomical therapeutic chemical class (ATC class), strength, 
package size, number and date of dispensed prescription.45
The Population’s
Education Registry (PER)
Information on highest attained education. In 2008 PER included 96.4% of the Danish 
population between 15 and 69 years of age.46
The Income Statistics Register Initiated in 1970. Contains information on the income and its composition (eg, salary, 
taxes and public transfer payments) on an individual level as registered by the Tax 
Administration’s registry.47
All national registries can be linked on an individual basis using the civil registration number administered at birth or immigration.41
of interest) and (2) a diagnosis of RA (the main exposure 
of interest)
Exposure
RA is the main exposure of interest. A cohort of incident 
cases of RA will be identified based on DANBIO and the 
Danish National Patient Registry (DNPR). Individuals 
registered with one of the following International Clas-
sification of Diseases codes in its 10th revision (ICD-10) 
in DANBIO are considered patients with RA: M05.9 (RA 
seropositive), M06.0 (RA seronegative) and M06.9 (RA 
unspecified). Furthermore, in the DNPR individuals with 
≥2 registrations from rheumatology departments with one 
of the mentioned ICD-10 codes (including also M05.8 
(other types of RA), not used in DANBIO) or the ICD-8 
code 712.39 (arthritis rheumatoides alia et non specifi-
cata), within a period of 90 days are considered patients 
with RA. This method has previously been validated with 
high degree of validity (positive predictive value ≈80%) 
and completeness.36
outcome/event
The outcome of interest is incident first-time SAB as iden-
tified in the Danish National S. aureus Bacteremia Data-
base. SAB relapses/reinfections will not be included. SAB 
events will be labelled ‘hospital-acquired’ (HA SAB) if 
the first blood culture with S. aureus is obtained 48 hours 
or more after admission to a hospital and non-hospital 
acquired (non-HA SAB) if it is obtained <48 hours after 
admission. The non-HA SAB may be further subdivided 
into healthcare-associated SAB (HCA SAB) and commu-
nity-acquired SAB (CA SAB) based on whether the patient 
has had recent hospital contact or not. Cases of SAB will 
further be classified with regards to the causative microor-
ganism as cases of methicillin-resistant S. aureus (MRSA) 
SAB or methicillin-sensitive S. aureus (MSSA) SAB.
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Follow-up
Follow-up starts at 31 December 1996, an individual’s 
18th birthday, or at the date of immigration, whichever 
comes last. Individuals are followed up until first-time 
SAB, emigration, death or 31 December 2017, which-
ever comes first. Incident patients with RA contribute 
with person-years in the RA cohort following diagnosis 
and until the end of follow-up. The remaining individ-
uals contribute person-years in the general population 
cohort. RA patients diagnosed after start of follow-up 
will contribute person-years in the general population 
cohort until date of RA diagnosis and in the RA cohort 
thereafter.
Covariates
Information on diseases known to affect SAB risk (eg, 
diabetes mellitus and hemodialysis) and use of prescrip-
tion medications (eg, glucose-lowering medication and 
TMP/SMX) will be obtained prior to baseline and 
during follow-up from the DNPR and the Register of 
Medicinal Product Statistics. Some conditions (eg, 
diabetes mellitus and prosthetic joint insertion) leaves 
the subject in ‘forever risk’ from the date of diagnosis/
operation and until the end of follow-up. Other inci-
dents, as invasive surgical procedures and dialysis 
procedures are considered temporary risk factors, and 
subjects are considered ‘at risk’ of one of these in 90 days 
after the procedure date. Patients with cancer (except 
non-melanoma skin cancer) are considered at risk until 
5 years after the last registration of a cancer diagnosis 
in the DNPR. Socioeconomic status will be evaluated 
by the highest attained educational level identified by 
the Population’s Education Registry and by the yearly 
average personal income level (3 years back) identified 
by the Income Statistics Register.
To allow for evaluation of RA specific risk factors, 
information specific to RA patients will be identified in 
DANBIO prior to and during follow-up (table 2). Infor-
mation on smoking habits is systematically collected 
annually in DANBIO and has a high degree of complete-
ness.37 DANBIO is the main source of information on 
antirheumatic treatments since, in Denmark, some drugs 
are administered from the hospital departments without 
prescription (bDMARDS, subcutaneous methotrexate, 
leflunomide and injections with glucocorticoids) and 
hence not registered in the Register of Medicinal Products 
Statistics. A recent audit in DANBIO found a coverage of 
98% for bDMARDs.38 Information on glucocorticoid use 
will be identified in both DANBIO and the Register of 
Medicinal Products Statistics (table 2).
Expected number of events
When identifying incident RA cases in the DNPR and 
DANBIO as described above, we expect to identify approx-
imately 500 SAB cases in the RA cohort. This is based on 
data from the annual report from The Danish National 
SAB Database.1 Thus, from year 1996 until 2017 ≈30 000 
SAB cases were reported whereof, in the last years, ~5% 
(4.7%–6.2%) occurred in patients with comorbid ‘rheu-
matic diseases’, corresponding ≈1500 cases in total (5% of 
30 000). The expected number of events is based on the 
conservative assumption that one-third of these patients 
will be incident patients with RA.
Since we have more detailed information on RA patients 
that have been followed in DANBIO (eg, smoking, disease 
activity, joint erosions and so on) compared with RA 
patients identified in the DNPR, we will consider limiting 
exposure to only RA according to DANBIO if the number 
of events is large enough for meaningful statistical anal-
ysis. In this case, the study period will be limited accord-
ingly to 2006 and onwards.
data analysis plan
The exact data analysis plan depends on data availability 
and number of events. IRs of SAB in the RA and in the 
general population cohorts will be calculated and multi-
variable Poisson regression models will be used to esti-
mate IRRs. IRRs will be presented crude (adjusted for age, 
sex and calendar year) and further adjusted for potential 
confounders. We will use a dynamic statistical method to 
assess the impact of an RA diagnosis while accounting for 
other possible and known risk factors (eg, socioeconomic 
status, comorbidities and dialysis procedures). The Lexis 
macro will be used to split follow-up time according to 
calendar time, age and exposure status (eg, comorbidities 
and socioeconomic status). Comorbidities will be entered 
as time-varying variables in the model.
The impact of risk factors for SAB in patients with RA 
compared with the general population will be analysed 
as events in the exposed time-period compared with 
events in the unexposed time-period using the multi-
variable Poisson regression model. If statistical interac-
tion is observed between RA and any of the potential or 
known risk factors, stratified analyses will be performed.
The impact of possible risk factors (antirheumatic 
treatment, disease duration, disease activity, joint 
erosions and smoking) for SAB among RA patients 
will be assessed. The number of covariates included in 
the final model will correspond the number of events 
in the RA population and will be prioritised according 
to a-priori assumption of clinical relevance. We plan to 
study the impact of different DMARD treatments as risk 
factors for SAB among patients with RA separately, alter-
natively grouped as for example, bDMARDs, tsDMARDs 
and csDMARDs.
Sensitivity analyses will include stratified analysis 
according to outcome defined as HA SAB, and non-HA 
SAB which can further be distinguished as HCA and CA 
SAB. The number of MRSA and MSSA SAB events in the 
RA and general population cohort will be presented. We 
do not expect the statistical power to allow us to perform 
separate analysis of risk factors for MRSA SAB due to 
an expected low number of cases.1 Further sensitivity 
analysis will be performed to assess any difference in IR 
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Table 2 Characteristics of patients with RA according to the DANBIO registry
Variable Description Value
CDAI Composite disease activity score of patient’s and 
doctor’s global assessment on a visual analogue scale
0.0–76.0
Disease duration Time passed from RA diagnosis until the first-time SAB Years
Erosive joint disease X-rays of hands and feet registered before the first-time 
SAB
Erosions/no erosions/unavailable
Autoantibody status ACPA and RF registered before SAB Positive/negative/unavailable
Smoking Smoking status registered as close to SAB as possible Previous/current/never/occasional/ 
unavailable
csDMARDs
Methotrexate, sulphasalazine, 
hydroxychloroquine, leflunomide
Current user: use within 90 days before SAB
Previous user: ever used >90 days prior to SAB
Non-user: Never used
Cumulated exposure: days on the drug (for current 
users)
Current/previous/non-user and 
cumulated exposure (days)
bDMARDs
Anti-TNFs, abatacept, 
secukinumab, IL6 inhibitors, 
ustekinumab, apremilast
Current user: use within 90 days before SAB
Previous user: ever used >90 days prior to SAB
Non-user: never used
Cumulated exposure: days on the drug (for current 
users)
Current/previous/non-user and 
cumulated exposure (days)
Rituximab Current user: last dose of rituximab was given within 12 
months prior to SAB
Previous user: ever used
Non-user: never used
Cumulated exposure: total dose (both current and 
previous users)
Current/previous/non-user and 
cumulated exposure (mg)
tsDMARDs
JAK inhibitors Current user: use within 90 days before SAB
Previous user: ever used more than 90 days prior to 
SAB
Non-user: never used
Cumulated exposure: days on the drug (for current 
users)
Current/previous/non-user and 
cumulated exposure (days)
Glucocorticoids (GCs)*
Oral and injectable (intramuscular 
and intraarticular) GCs
Current user: use within 90 days before SAB
Previous user: ever used >90 days prior to SAB
Non-user: never used
Cumulated exposure: will be calculated as 
prednisolone-equivalent dose for current users as 
described elsewhere10
Current/previous/non-user and 
cumulated exposure (mg)
*Use of GCs will be identified in both DANBIO and the Register of Medicinal Products Statistics.
CDAI, clinical disease activity index; IL6 inhibitors, interleukin-6 inhibitors (tocilizumab, sarilumab); JAK inhibitors, Janus kinase inhibitors 
(baricitinib, tofacitinib); RA, rheumatoid arthritis; SAB, Staphylococcus aureus bacteremia; anti-TNF, tumor necrosis factor inhibitors 
(adalimumab, golimumab, etanercept, certolizumab pegol, infliximab); bDMARDs, biologic disease-modifying antirheumatic drugs; 
csDMARDs, conventional synthetic DMARDS; tsDMARDs, targeted synthetic DMARDs.
between the RA cohort identified in DANBIO and the full 
RA cohort identified by both DANBIO and the DNPR. 
Missing data will be handled by appropriate statistical 
methods, for example, multiple imputations.
Data will be hosted and anonymised by Statistics 
Denmark and data will be processed using the statistical 
software SAS. Data access is expected in June 2019. Data 
analysis will start when access is obtained and is expected 
to end in January 2020.
Patient and public involvement
The study hypotheses and design were discussed with a 
trained patient research partner both in the very begin-
ning of the brainstorming phase of the study and later 
when the study hypotheses were formed. The purpose 
was to secure that possible risk factors evaluated were 
also important from a patient perspective, for example, 
we agreed on risk associated with different treatments, 
disease duration and disease activity.
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EthICs And dIssEMInAtIon
All data will be handled in accordance with the General 
Data Protection Regulation (EU) 2016/679. Data 
processing agreements are set up between all data proces-
sors and the data owner (the Capital Region of Denmark). 
Data handling and data processing agreements are 
approved by the Capital Region of Denmark. Access to 
data from The Register of Medicinal Product Statistics is 
approved by Sundhedsdatastyrelsen, data from DANBIO 
are approved by The Danish Clinical Registries (RKKP) 
and data from the Danish National SAB Database are 
approved by Statens Serum Institut. Statistics Denmark 
has authorised the research institution and granted 
permission to linkage of data based on a written applica-
tion. No ethical approval is necessary in Denmark when 
handling registry data only. The results will be presented 
in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology initiative39 as orig-
inal articles in international peer-reviewed journals and 
at medical conferences. Both positive and negative results 
will be published.
FuturE PErsPECtIvEs
The outcome of SAB in patients with RA remains to be 
investigated in further detail. One study on the subject 
suggested that patients with RA are at increased risk of 
a fatal outcome after SAB and that multiple metastatic 
infections in joints and bones are common.40 When 
the disease burden of SAB in Danish patients with RA 
has been established in the current study, we plan to 
perform further studies on outcome after SAB including 
all-cause mortality, incidence of secondary infections and 
frequency of recurrent SAB in patients with RA compared 
with non-RA patients. We plan to identify risk factors for 
poor outcome that can guide physicians in the evaluation 
of a SAB patient with comorbid RA.
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